Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Chen, Chih Chieh ^a   Er, Tze Kiong ^b,c,d   Liu, Yen Yi ^a   Hwang, Jenn Kang ^a   Barrio, Maria Jesus ^e   Rodrigo, Maximiliano ^e   Garcia Toro, Enrique ^e   Herreros Villanueva, Marta ^e  

^a NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GUANOSINE TRIPHOSPHATE; K RAS PROTEIN;

ARTICLE; CRYSTAL STRUCTURE; GENE MUTATION; HUMAN; MATHEMATICAL ANALYSIS; MATHEMATICAL PARAMETERS; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; MUTANT; ONCOGENE K RAS; POTENTIAL OF MEAN FORCE SIMULATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; ROOT MEAN SQUARE DEVIATION; WILD TYPE;

AMINO ACID SUBSTITUTION; COMPUTATIONAL BIOLOGY; GUANOSINE TRIPHOSPHATE; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; THERMODYNAMICS;

EID: 84874248179     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055793     Document Type: Article

References (62)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA: a cancer journal for clinicians 61: 69-90.
2. American Cancer Society. Cancer Facts & Figures 2009. Available: http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/. Accessed 2013 Jan 7.
3. (2004) US Food and Drug Administration. FDA approves Erbitux for colorectal cancer. Www Fda Gov.
4. (2007) US Food and Drug Administration. FDA approves Vectibix (panitumumab) to treat metastatic colorectal carcinoma. Www Fda Gov.
5. KRAS mutations and epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer. Technol Eval Cent Assess Program Exec Summ 23: 1-3.
6. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, et al. (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27: 2091-2096.
7. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England journal of medicine 359: 1757-1765.
8. McGrath JP, Capon DJ, Smith DH, Chen EY, Seeburg PH, et al. (1983) Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene. Nature 304: 501-506.
9. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, et al. (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British journal of cancer 96: 1166-1169.
10. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26: 374-379.
11. Park JH, Kim IJ, Kang HC, Shin Y, Park HW, et al. (2004) Oligonucleotide microarray-based mutation detection of the K-ras gene in colorectal cancers with use of competitive DNA hybridization. Clin Chem 50: 1688-1691.
12. Brink M, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, et al. (2003) K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 24: 703-710.
13. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, et al. (2012) Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 61: 847-854.
14. Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT, et al. (2012) Colorectal cancer: a tale of two sides or a continuum? Gut 61: 794-797.
15. Herreros-Villanueva M, Rodrigo M, Claver M, Muniz P, Lastra E, et al. (2011) KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Molecular biology reports 38: 1315-1320.
16. Edkins S, O'Meara S, Parker A, Stevens C, Reis M, et al. (2006) Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 5: 928-932.
17. Seeburg PH, Colby WW, Capon DJ, Goeddel DV, Levinson AD, (1984) Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 312: 71-75.
18. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA, (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 90: 675-684.
19. Malumbres M, Barbacid M, (2003) RAS oncogenes: the first 30 years. Nat Rev Cancer 3: 459-465.
20. Baselga J, Rosen N, (2008) Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol 26: 1582-1584.
21. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995.
22. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, et al. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6: 279-286.
23. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, et al. (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648.
24. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, et al. (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19: 508-515.
25. Guerrero S, Casanova I, Farre L, Mazo A, Capella G, et al. (2000) K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 60: 6750-6756.
26. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, et al. (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA: the journal of the American Medical Association 304: 1812-1820.
27. Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, et al. (2012) Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers. Clinical cancer research: an official journal of the American Association for Cancer Research.
28. Chen J, Ye Y, Sun H, Shi G (2012) Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis. Cancer Chemother Pharmacol.
29. Mao C, Huang YF, Yang ZY, Zheng DY, Chen JZ, et al. (2012) KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: A systematic review and meta-analysis. Cancer.
30. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, et al. (2012) Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab. Journal of clinical oncology: official journal of the American Society of Clinical Oncology.
31. Ward RL, Todd AV, Santiago F, O'Connor T, Hawkins NJ, (1997) Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis. Cancer 79: 1106-1113.
32. Bos JL, Toksoz D, Marshall CJ, Verlaan-de Vries M, Veeneman GH, et al. (1985) Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia. Nature 315: 726-730.
33. Sloan SR, Newcomb EW, Pellicer A, (1990) Neutron radiation can activate K-ras via a point mutation in codon 146 and induces a different spectrum of ras mutations than does gamma radiation. Mol Cell Biol 10: 405-408.
34. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, et al. (2012) Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology.
35. Gajate P, Sastre J, Bando I, Alonso T, Cillero L, et al. (2012) Influence of KRAS p.G13D Mutation in Patients With Metastatic Colorectal Cancer Treated With Cetuximab. Clinical colorectal cancer.
36. Modest DP, Stintzing S, Laubender RP, Neumann J, Jung A, et al. (2011) Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Anti-cancer drugs 22: 913-918.
37. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, et al. (2000) Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 9: 1193-1197.
38. Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, et al. (2002) Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 13: 1438-1446.
39. Chen CC, Hwang JK, Yang JM, (2006) (PS)2: protein structure prediction server. Nucleic Acids Research 34: W152-W157.
40. Chen CC, Hwang JK, Yang JM, (2009) (PS)2-v2: template-based protein structure prediction server. Bmc Bioinformatics 10: 366.
41. Yang JM, Chen CC, (2004) GEMDOCK: a generic evolutionary method for molecular docking. Proteins-Structure Function and Bioinformatics 55: 288-304.
42. Hsu KC, Chen YF, Lin SR, Yang JM, (2011) iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis. Bmc Bioinformatics 12Suppl 1: S33.
43. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, et al. (2005) GROMACS: fast, flexible, and free. Journal of computational chemistry 26: 1701-1718.
44. Schuttelkopf AW, van Aalten DM, (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta crystallographica Section D, Biological crystallography 60: 1355-1363.
45. Darden T, York D, Pedersen L, (1993) Particle mesh Ewald: An N{dot operator}log(N) method for Ewald sums in large systems. The Journal of Chemical Physics 98: 10089-10092.
46. PyMOL. Available: http://www.pymol.org. Accessed 2013 Jan 7.
47. Parthasarathy S, Murthy MR, (2000) Protein thermal stability: insights from atomic displacement parameters (B values). Protein Engineering 13: 9-13.
48. Torrie GM, Valleau JP, (1977) Non-Physical Sampling Distributions in Monte-Carlo Free-Energy Estimation- Umbrella Sampling. Journal of Computational Physics 23: 187-199.
49. Kirkwood JG, (1935) Statistical Mechanics of Fluid Mixtures. Journal of Chemical Physics 3: 300-313.
50. Kumar S, Bouzida D, Swendsen RH, Kollman PA, Rosenberg JM, (1992) The Weighted Histogram Analysis Method for Free-Energy Calculations on Biomolecules.1. The Method. Journal of computational chemistry 13: 1011-1021.
51. Roux B, (1995) The Calculation of the Potential of Mean Force Using Computer-Simulations. Computer Physics Communications 91: 275-282.
52. Er TK, Chang YS, Yeh KT, Chang TJ, Chang JG, (2010) Comparison of two different screening methods for the KRAS mutation in colorectal cancer. Clinical laboratory 56: 175-186.
53. Chen YL, Chang YS, Chang JG, Wu SM, (2009) Genotyping of K-ras codons 12 and 13 mutations in colorectal cancer by capillary electrophoresis. Journal of chromatography A 1216: 5147-5154.
54. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
55. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A, (2009) Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 205: 858-862.
56. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, et al. (2009) Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 6: 519-527.
57. Bollag G, McCormick F, (1995) Intrinsic and GTPase-activating protein-stimulated Ras GTPase assays. Methods Enzymol 255: 161-170.
58. Al-Mulla F, Milner-White EJ, Going JJ, Birnie GD, (1999) Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. J Pathol 187: 433-438.
59. Futatsugi N, Tsuda M, (2001) Molecular dynamics simulations of Gly-12->Val mutant of p21(ras): dynamic inhibition mechanism. Biophys J 81: 3483-3488.
60. Messner I, Cadeddu G, Huckenbeck W, Knowles HJ, Gabbert HE, et al. (2012) KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. J Cancer Res Clin Oncol.
61. Chang DZ, Kumar V, Ma Y, Li K, Kopetz S, (2009) Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. Journal of hematology & oncology 2: 18.
62. Gideon P, John J, Frech M, Lautwein A, Clark R, et al. (1992) Mutational and kinetic analyses of the GTPase-activating protein (GAP)-p21 interaction: the C-terminal domain of GAP is not sufficient for full activity. Molecular and Cellular Biology 12: 2050-2056.